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20-O-Methyl at 20-mer Guide Strand 30 Termini
May Negatively Affect Target Silencing Activity
of Fully Chemically Modified siRNA
Sarah M. Davis,1 Jacquelyn Sousa,1 Lorenc Vangjeli,1 Matthew R. Hassler,1 Dimas Echeverria,1 Emily Knox,1
Anton A. Turanov,1 Julia F. Alterman,1 and Anastasia Khvorova1,2
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Molecular Medicine, University of Massachusetts Medical
School, Worcester, MA 01605, USA
Small interfering RNAs (siRNAs) have the potential to treat a
broad range of diseases. siRNAs need to be extensively chemi-
cally modified to improve their bioavailability, safety, and sta-
bility in vivo. However, chemical modifications variably impact
target silencing for different siRNA sequences, making the ac-
tivity of chemically modified siRNA difficult to predict. Here,
we systematically evaluated the impact of 30 terminal modifica-
tions (20-O-methyl versus 20-fluoro) on guide strands of
different length and showed that 30 terminal 20-O-methyl modi-
fication negatively impacts activity for >60% of siRNA se-
quences tested but only in the context of 20- and not 19- or
21-nt-long guide strands. These results indicate that sequence,
modification pattern, and structure may cooperatively affect
target silencing. Interestingly, the introduction of an extra 20-
fluoro modification in the seed region at guide strand position
5, but not 7, may partially compensate for the negative impact
of 30 terminal 20-O-methyl modification. Molecular modeling
analysis suggests that 20-O-methyl modification may impair
guide strand interactions within the PAZ domain of argo-
naute-2, which may affect target recognition and cleavage, spe-
cifically when guide strands are 20-nt long. Our findings
emphasize the complex nature of modified RNA-protein inter-
actions and contribute to design principles for chemically
modified siRNAs.
INTRODUCTION
Small interfering RNA (siRNA) interacts with the RNA-induced
silencing complex (RISC) to degrade complementary mRNA and pre-
vent protein translation, making it a powerful tool for silencing dis-
ease-causing genes.1 Extensive chemical modification improves the
stability of siRNAs in vivo, which is especially important for conju-
gated siRNAs to achieve long-term target silencing.2
A common siRNAmodification site is the 20 position of ribose, where
20-O-methyl (20-OMe) and 20-fluoro (20-F) are frequently used. The
majority of clinical-stage compounds is fully modified and possess
a larger fraction of 20-OMe modifications than 20-F modifications
because the former is more stabilizing against nucleases.3 Indeed,
an increase of 20-OMe content enhances siRNA potency and duration
of effect in vivo.4 However, the inclusion of 20-OMe at certain posi-
tions can negatively impact activity—e.g., guide strand position 14
does not tolerate 20-OMe.4–6
Whereas chemical modifications are essential for conjugated siRNA
efficacy in vivo, they may negatively impact one or more steps of
RISC function, including the following: when (1) the siRNA duplex
is loaded into RISC, and the passenger strand is released; (2) the
mRNA target is recognized by guide strand-loaded RISC; (3) the
siRNA-mRNA target adopts the optimal configuration for cleavage;
(4) the siRNA-mRNA target undergoes endonucleolytic cleavage;
and (5) the product is released. However, the individual and com-
bined effects of different types of modifications, like 20-OMe and
20-F on RISC function, are not well understood.
Many siRNA sequences that are active when unmodified lose activity
when they are extensively chemically modified.5 Moreover, chemical
modification patterns variably impact the efficacy of different se-
quences. Therefore, the screening of multiple chemical variants for
each siRNA sequence is currently required to generate compounds
with optimal stability and activity. A better understanding of general
chemical modification rules (i.e., those applicable to many different
sequences) may reduce the amount of effort required to perform these
extensive screens.
Here, we demonstrate that 30 terminal 20-OMe modification of 20-
but not 19- or 21-mer guide strands may reduce the activity of fully
modified, asymmetric siRNAs and that this negative effect may be
partially compensated by including an additional 20-F modification
at guide strand position 5. Preliminary structural modeling provides
a potential explanation for these results and emphasizes the
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complexity and dynamic nature of chemically modified siRNA-RISC
interactions.
RESULTS
20-OMe at the 30 Termini of 20-mer Guide Strands Negatively
Impacts Target Silencing for Fully Modified, Asymmetric siRNAs
To evaluate the impact of position-specific chemical modification
changes, we utilized an asymmetric siRNA, fully chemically modified
with alternating 20-OMe and 20-F groups (i.e., the standard modifica-
tion pattern described by Allerson et al.7) (Figure 1). In this configu-
ration, a 20-mer guide strand is paired to a 15-mer passenger strand,
creating a single-stranded phosphorothioate (PS) tail on the 30 end of
the guide strand that contributes to cellular uptake, likely similarly to
the mechanism used by antisense oligonucleotides.8,9 When conju-
gated to cholesterol, these compounds are efficiently internalized by
all cell types via early endosome antigen-1 (EEA1)-associated endocy-
tosis10 and result in productive silencing in vitro and in vivo,2 which
simplifies logistics for in vitro screens to evaluate siRNA efficacy.
We observed that incorporating 20-OMe at 30 guide strand termini
negatively impacted siRNA activity for some sequences. To investi-
gate this phenomenon further and systematically, we synthesized a
panel of 16 siRNAs targeting eight different sequences within three
genes; the two siRNAs for each sequence differed only in the type
of modification (i.e., 20-OMe versus 20-F) on the 30 end of their guide
strand (Figure 2). We treated HeLa cells with these siRNAs for 72 h
and measured target mRNA expression levels using Dual-Glo Lucif-
erase or Quantigene 2.0 RNA assay systems (see Materials and
Methods). To ensure that any differences we identified were robust,
each siRNA was evaluated at seven concentrations; these dose re-
sponses and a summary of results are shown in Figure 2 and Table 1.
The incorporation of the 20-OMe modification at 30 guide strand
termini had a statistically significant impact on efficacy for five of the
eight sequences tested (Figure 2B). Figure 2C plots target mRNA
expression levels after treatment with the top dose (i.e., 1.5 mM) of
each siRNA with 20-F at guide strand position 20. Figure 2D plots
the differences in target mRNA expression levels observed at the top
dose when 20-OMe replaces 20-F at guide strand position 20. All
siRNAs show decreased efficacy at this dose except for HTT_10146
and HTT_1219, for which target mRNA expression levels decreased
Figure 1. siRNA Chemical Scaffold Used in this
Study
(A) Legend showing corresponding chemical structures
for chemistries used in this study. (B) Schematic repre-
sentation of asymmetric siRNA with an alternating 20-
OMe/-F chemical pattern.
by %1%. Figure 2E plots percent differences in
the areas under the dose response curves
(AUCs) in Figure 2B. For each test concentration
of siRNA, if the replacement of 20-F with 20-OMe
at 30 guide strand termini increased targetmRNA
expression, then there is a positive shift along the y axis, which increases
the AUC. Thus, a positive change in the AUC reflects an overall nega-
tive change in efficacy across all treatment concentrations. For all
siRNAs except HTT_10125, AUCs increase. Positive changes in
AUCs also reflect negative changes in potency, because if the dose
required to achieve similar target mRNA expression levels increases,
then there is a positive shift along the x axis. The half-maximal inhib-
itory concentration (IC50) is also a valuable measure of potency when it
can be calculated from a sigmoidal curve. Figure 2F plots fold changes
in IC50 values. It shows that for all siRNAs except HTT_1257, the
replacement of 20-F with 20-OMe at guide strand position 20 increases
IC50 values by 1.3- to 7.3-fold. Interestingly, the most active sequences
(i.e., those that demonstrate the highest amounts of silencing at the top
treatment dose, lowest AUCs, and lowest IC50 values—sFLT1-
i13_2283, sFLT1-e15a_2519, and HTT_10150) are the most negatively
impacted by 20-OMe at guide strand position 20 (Table 1; Figures 2C,
2E, and 2F). Similarly, the efficacies of the least effective sequences (i.e.,
HTT_10146, which demonstrates the lowest amount of target silencing
at the top treatment dose, andHTT_10125 andHTT_1219, which have
the highest AUCs) are the least negatively impacted, as reflected by low
or negative percent differences in AUCs (Figure 2E) and nonsignificant
p values (Figure 2B). This suggests that there are other parameters
limiting the efficacies of these sequences that outweigh the contribution
of the 30 end guide strand modification. The replacement of 20-F with
20-OMe at guide strand position 20 also reduced the activity of sFLT1-
i13_2283 siRNA with a 20-mer guide strand and 14-mer passenger
strand (Figure S1; Table S1), indicating that the length of the single-
stranded PS tail (i.e., 6 or 5) does not impact its negative effects.
These data show that replacing 20-F with 20-OMe at 30 guide strand
termini reduces the target silencing activity of siRNAs with guide
strands that are 20 nt long and conform to the standard 20-F/ 20-
OMe alternating pattern, described by Allerson et al.7Within the con-
texts of this guide strand length and chemical pattern, the negative
impacts of this modification appear generally applicable to many
different siRNA sequences. However, more active sequences demon-
strated bigger reductions in activity, so we next investigated whether
the negative contribution of 30 guide strand terminal 20-OMe could be
alleviated for the three most active siRNAs—sFLT1-i13_2283, sFLT1-
e15a_2519, and HTT_10150—by enhancing seed-based (i.e., guide
strand positions 2–8) target recognition.
www.moleculartherapy.org
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20-F at Position 5 of 20-mer Guide Strands with 30 Terminal 20-
OMe Improves Target Silencing for Fully Modified, Asymmetric
siRNAs
20-F modifications likely cause tighter base stacking than 20-OMe
modifications11,12 and are therefore predicted to enhance target bind-
ing and in turn, improve siRNA activity. Thus, we replaced 20-OMe
with 20-F at guide strand position 5 in the seed region (Figure 3A)
and measured target mRNA expression levels to see if this modifica-
tion change could improve the activity of siRNAs containing 30 guide
strand terminal 20-OMe.
Figure 3 shows that incorporating 20-F at position 5 had a compensa-
tory effect on three different siRNAs, for which target silencing activ-
ities were significantly, negatively affected by 20-OMe modification at
30 guide strand termini. The summary of changes in efficacy and po-
tency are shown in Table 1. This chemical modification enhanced
target mRNA expression levels at the maximum treatment dose
(1.5 mMsiRNA) (Figure 3D) and over the full range of siRNA concen-
trations tested (Figure 3E) at significance levels <0.005 (Figure 3B)
and also decreased IC50 values by 1.2- to 1.9-fold (Figure 3F).
Increased activity was also demonstrated for sFLT1-i13_2283 and
sFLT1-e15a_2519 siRNAs with passenger strands that deviated
from the alternating 20-F/20-OMe chemical pattern by including
80% 20-OMe modifications (Figure S2; Table S2), suggesting that
the chemical pattern of the passenger strand does not impact the pos-
itive effects of this modification change.
The siRNA seed region corresponds to guide strand positions 2–8, so
we next investigated if the enhancement in activity observed when 20-
OMe was replaced by 20-F in the seed was specific to position 5. Inter-
estingly, the incorporation of 20-F at guide strand position 7 did not
significantly improve activity for the siRNAs tested; in fact, we
observed a minor negative impact (Figure S2; Table S2). These results
suggest that conformational fitting within the seed, rather than target
affinity within the seed, is the bigger contributing factor to changes in
siRNA activity.
20-F modifications indeed have slightly higher affinity to RNA
compared to 20-OMe,13 but 20-F is also smaller in size and thus, af-
fords better base-stacking interactions,11 which may increase duplex
stability and/or enhance seed-based target scanning. To investigate
whether these properties contributed to our observations, we
measured the impact of these modifications at positions 5, 7, and
20 on the thermal melting temperatures (Tms) of sFLT1-i13_2283
Figure 2. 20-O-Methyl at 30 Termini of 20-mer Guide Strands Decreases Activity of Fully Modified, Asymmetric siRNAs
(A) Schematic representations of chemical modification scaffolds used; symbols next to each schematic are used in graphs shown in (B). Legend shows corresponding
chemical structures for 20-ribosemodifications. (B) Dose response results (n = 3,mean ±SD). Target name and start site of target sequence are indicated in each graph. HeLa
cells were treated with siRNAs at concentrations shown for 72 h. mRNA levels were measured using the Dual-Glo Luciferase Assay System (sFLT1-i13, sFLT1-e15a) or
Quantigene 2.0 RNA Assay (HTT) and calculated as a percent of those from untreated cell controls. Statistical outliers were excluded from analyses but are shown in the
graphs as solid data points. Nonlinear regression curves with R2 < 0.8 are displayed as dashed rather than solid lines. p values displayed on each graph were calculated by
two-way ANOVA. (C) Target mRNA expression with 1.5 mMof each siRNAwith 20-F at guide strand position 20. (D) Differences in target mRNA expression with 1.5 mMof each
siRNA when 20-OMe replaces 20-F at guide strand position 20. (E) Percent differences in AUCs. (F) Fold changes in IC50 values, calculated by dividing the value obtained from
siRNAs with 20-OMe at guide strand position 20 by the value obtained from siRNAs with 20-F at guide strand position 20; if this number was <1, then the negative reciprocal is
shown. (D–F) Positive or negative values indicate increases or decreases in values when 20-OMe replaces 20-F at guide strand position 20.
Molecular Therapy: Nucleic Acids
268 Molecular Therapy: Nucleic Acids Vol. 21 September 2020
and sFLT1-e15a_2519 siRNA guide and passenger strands and at po-
sitions 5 and 7 on the Tms of sFLT1-i13_2283 and sFLT1-e15a_2519
siRNA guide strand seed regions and their complementary RNAs.
Introduction of an Additional 20-F in the Guide Strand Seed Does
Not Measurably Impact Overall siRNA Duplex or Local Guide
Strand Seed-Target Tms
In order to better define the mechanism(s) supporting our results, we
first measured Tms for sFLT1-i13_2283 and sFLT1-e15a_2519
siRNA duplexes. We observed no measurable differences between
siRNAs with 20-F or 20-OMe at position 20 or between siRNAs
with 30 end 20-OMe and 20-F or 20-OMe at position 5 (Figure 4). Du-
plexes targeting sFLT1-i13 with 14-mer passenger strands were
included as a proof-of-principle control (Figure 4). As expected,
Tms significantly decreased when a 14-mer instead of 15-mer passen-
ger strand was used, but again, there was no change in Tm when 20-
OMe was included at the 30 guide strand terminus or when 20-F was
added at guide strand position 5 (Figure 4). These results suggest that
the negative impact of 20-OMe at guide strand position 20 and the
positive impact of 20-F at guide strand position 5 are not due to
changes in overall duplex Tm.
The increase of duplex Tm in the context of extensively chemically
modified siRNAs could impede RISC loading by inhibiting unwinding
of the passenger strand prior to its release.14,15 However, if this were the
primary mechanism influencing our results, then we would expect to
see decreases in siRNA activity when 20-F instead of 20-OMe is included
at guide strand positions 5 and 20, which is the opposite of what we
observe. Therefore, these modification changes demonstrating no
measurable impact on overall duplex Tm support our observations
of their impacts on efficacy. Therefore, we next considered how
including an additional 20-F at guide strand position 5 might influence
the Tm between an siRNA guide strand and its RNA target within the
seed. 20-F modification increases Tm, and this effect is more pro-
nounced when consecutive nucleotides are modified.3 Since initial
seed interactions are impacted by local Tm, the stretch of 20-F modifi-
cations from positions 4–6 could drive guide strand-loaded RISC to
recognize its target with higher affinity and thus, positively impact
target silencing. To test this, we synthesized single constructs that
each included the following: (1) an 8-mer matching sFLT1-i13_2283
or sFLT1-e15a_2519 siRNA guide strand positions 1–8 in sequence
and chemistry (i.e., cholesterol conjugated, with modifications as indi-
cated in Figure 5A), (2) a UUCG tetraloop, and (3) a 7-mer unmodified
RNA sequence reverse complementing sFLT1-i13_2283 or sFLT1-
e15a_2519 positions 2–8 (i.e., the seed region) representing the RNA
target. Initial experiments demonstrated insufficient hybridization be-
tween the 8- and 7-mer sequences to measure Tm, likely due to their
short length and adenine A/ U richness. The additional stability offered
by the UUCG tetraloop made it possible to measure Tms for these se-
quences within a hairpin structure. Measured Tms are therefore prox-
ies for Tms for each guide strand and target within the seed. If the ad-
ditions of 20-F at guide strand position 5 or 7 resulted in changes in
thermostability within the seed region, then relative changes in Tm
would be observed using this strategy. However, the results of this
experiment show negligible changes in Tm when these chemical modi-
fication patterns are applied. These data suggest that the changes in ac-
tivity shown in Figures 3 and S2 are not likely due to changes in siRNA






















20-F at Position 5
Target
% Target mRNA Expression with
1.5 mM siRNA
Difference % Target mRNA




13.3 55.7 15.7 42.3 40.0
sFLT1-
e15a_2519
15.7 18.3 11.3 2.7 7.0
HTT_462 18.3 23.5 N/D 5.1 N/D
HTT_10125 28.7 33.4 N/D 4.7 N/D
HTT_10146 39.5 39.1 N/D 0.3 N/D
HTT_10150 16.2 27.8 18.3 11.6 9.5
HTT_1219 30.1 28.8 N/D 1.3 N/D
HTT_1257 30.9 38.4 N/D 7.5 N/D
Target Area under Curve




410.3 597.0 486.1 37.1 20.5
sFLT1-
e15a_2519
471.1 626.3 566.4 28.3 10.0
HTT_462 531.1 679.2 N/D 24.5 N/D
HTT_10125 592.9 575.2 N/D 3.0 N/D
HTT_10146 550.2 620.2 N/D 12.0 N/D
HTT_10150 524.2 627.1 565.8 17.9 10.3
HTT_1219 666.7 669.1 N/D 0.4 N/D
HTT_1257 553.0 642.0 N/D 14.9 N/D
Target IC50 Value (nM) Fold Change IC50 Value
sFLT1-
i13_2283
1.5 10.9 6.0 7.3 1.8
sFLT1-
e15a_2519
6.8 33.2 28.8 4.9 1.2
HTT_462 91.6 142.3 N/D 1.6 N/D
HTT_10125 122.9 208.7 N/D 1.7 N/D
HTT_10146 64.3a 119.4 N/D 1.9 N/D
HTT_10150 44.4 166.8 88.4 3.8 1.9
HTT_1219 164.0 213.0 N/D 1.3 N/D
HTT_1257 227.3 210.8 N/D 1.1 N/D
Values are from Figures 2 and 3.When looking at differences, positive or negative values
indicate an increase or decrease in values with the application of the indicated modifi-
cation change. IC50 fold change was calculated by dividing the value obtained with the
indicated modification change by the value obtained without it. However, if this number
was <1, then the negative reciprocal is listed (e.g., 0.75, or a drop of 25% from the orig-
inal value, is reported as 1.3-fold change). N/D, no data.
aThe R2 value for the fitted curve used to calculate the IC50 value <0.8.
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Guide Strand Length Dictates the Extent toWhich 30 Terminal 20-
OMe Negatively Impacts the Activity of Fully Modified,
Asymmetric siRNAs
There are multiple siRNA structures used in research and in the
clinic, and the general belief is that guide strand length, within a
range of 19–25 nt, minimally impacts siRNA efficacy. However,
the type of 30 terminal modification on a guide strand may affect
its fitting within the PAZ domain of argonaute-2 (Ago2).16,17 To
investigate whether guide strand length impacts the observed nega-
tive effects of 30 guide strand terminal 20-OMe modification on
siRNA activity, we synthesized 5 additional siRNA sequences as
19- and 21-mers with 20-F or 20-OMe 30 terminal modification (Fig-
ures S3 and S4).
To our great surprise, when 20-OMe was included at the 30 end of 19-
(Figure S3; Table S3) or 21-mer guide strands (Figure S4; Table S5),
there were small or no significant negative impacts on siRNA efficacy.
For siRNAs with 19-mer guide strands, HTT_10125 and HTT_1257
demonstrated statistically worse efficacy when 20-OMe was included
at the 30 end of their guide strands instead of 20-F (Figure S3). However,
with a 19-mer guide strand,HTT_1257 showed less than a 6 percent dif-
ference inAUCs (Table S3), considerably less than the 15 percent differ-
ence demonstrated by this same sequence with a 20-mer guide strand
(Table 1). For HTT_10125, the percent difference in AUCs indeed in-
creases in the context of a 19 (Table S3)- versus 20 (Table 1)-mer guide
strand, but the averagedifference inmRNAexpression levels at the top 3
doses is 4 times lower (Table S4). For siRNAswith 21-mer guide strands,
Figure 3. 20-Fluoro at Position 5 of 20-mer Guide Strands Increases Activity of Fully Modified, Asymmetric siRNAs with 20-O-Methyl at 30 Guide Strand
Termini
(A) Schematic representations of chemical modification scaffolds used; symbols next to each schematic are used in graphs shown in (B). Legend shows corresponding
chemical structures for 20-ribose modifications. (B) Dose-response results (n = 3, mean ± SD). Target name and start site of target sequence are indicated in each graph.
HeLa cells were treated with siRNAs at concentrations shown for 72 h. mRNA levels were measured using the Dual-Glo Luciferase Assay System (sFLT1-i13, sFLT1-e15a) or
Quantigene 2.0 RNA Assay (HTT) and calculated as a percent of those from untreated cell controls. Statistical outliers were excluded from analyses but are shown in the
graphs as solid data points. p values displayed on each graph were calculated by two-way ANOVA. (C) Target mRNA expression with 1.5 mM of each siRNA with 20-OMe at
guide strand position 20. (D) Differences in target mRNA expression with 1.5 mMof each siRNA when 20-F replaces 20-OMe at guide strand position 5. (E) Percent differences
in AUCs. (F) Fold changes in IC50 values, calculated by dividing the value obtained from siRNAs with 2
0-F at guide strand position 5 by the value obtained from siRNAs with 20-
OMe at guide strand position 20; if this number was <1, then the negative reciprocal is shown. (D–F) Negative values indicate decreases in values when 20-F replaces 20-OMe
at guide strand position 5.
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HTT_462 and HTT_1257 showed significant changes in efficacy when
20-OMe, instead of 20-F, was included at the 30 end of their guide strands
but performed better with guide strands containing 30 terminal 20-OMe
instead of 20-F, as evidenced by decreased mRNA expression at the top
treatment dose and lower AUCs (Figure S4; Table S5). These results
indicate that both siRNA structure and chemical modification pattern
can cooperatively affect RISC interactions, and thus, both parameters
should be considered when designing siRNAs.
We have a lot of experience using asymmetric siRNAs, which are effi-
ciently internalized by cells when hydrophobically modified,2 but the
more symmetric 21-mer guide/19-mer passenger strand siRNA structure
is widely used. The length of the guide strand determined the degree to
which including 20-OMe at 30 guide strand termini decreased efficacy
for asymmetric siRNAs—this modification negatively impacted activity
for siRNAs with 20-mer guide and 15-mer passenger strands, but did
not for 19-/ 15-mer or 21- /15-mer siRNAs. We next investigated if this
modification affected the activity of more conventionally structured 21-
mer guide/19-mer passenger siRNAs. Unfortunately, only one sequence
maintained efficacy, whereas others silenced <50% of target mRNA (Fig-
ure S5; Table S6),making any small variations in activity between siRNAs
with guide strands containing 30 20-OMe or 20-F difficult to detect. The
structures of siRNAs variably impact different sequences,2 and the se-
quences tested were originally selected for their activity in screens using
the 20-mer guide/15-mer passenger strand asymmetric siRNA structure.
Therefore, these sequences likely particularly benefitted fromreductionof
the passenger strand, which can contribute to more efficient passenger
strand release and higher efficacy for some sequences.2,14,15
DISCUSSION
To date, there are no publications comparing the impacts of 30 guide
strand terminal 20-OMe versus 20-F modification on siRNA activity.
Figure 4. Introduction of 20-O-Methyl at Guide Strand Position 20 and 20-Fluoro at Guide Strand Position 5 Does Not Impact the Thermal Melting
Temperatures of Fully Modified, Asymmetric siRNA Duplexes
(A) Schematic representations of guide strand chemical modification patterns used; symbols next to each schematic are used in graphs shown in (B). Legend shows
corresponding chemical structures for 20-ribosemodifications. (B) Thermal melt curves for siRNAs. Target name, start site of target sequence, and length of paired passenger
strands are indicated in graphs; Tm values are displayed in graph legends.
www.moleculartherapy.org
Molecular Therapy: Nucleic Acids Vol. 21 September 2020 271
Here, we demonstrate that including 20-OMe instead of 20-F at guide
strand 30 termini reduces siRNA efficacy and/or potency for multiple
siRNA sequences and that this effect depends on the length of the
guide strand. Interestingly, we also show that introducing an addi-
tional 20-F modification in the guide strand seed partially compen-
sates for this negative effect for 3 active sequences.
Our finding that the positive impact of 20-F modification is specific to
position 5 and not 7 is consistent with previous findings. Salomon
et al.18 report that nucleotides 2–5 more prominently influence the
initial binding of guide strand-loaded RISC to its target RNA, whereas
nucleotides 6–8 largely slow the subsequent dissociation of RISC from
its target. Although these data support the inclusion of 20-F at guide
strand position 5, they may increase off-targeting activity—an impor-
tant issue to consider, especially for high-affinity seed sequences.19
The replacement of 20-OMe with 20-F at guide strand position 5
may also negatively impact duplex stability against nucleases, but
this is difficult to determine experimentally, because all fully chemi-
cally modified siRNAs are very stable in vitro (with >24- to 48-h
half-lives in 50% serum).2,7,20 Long-term in vivo studies will be
required to detect changes in nuclease stability caused by this single
modification change within fully chemically modified siRNAs and
will be necessary to fully assess the utility of this design feature.
The positive impact of 20-F at guide strand position 5 may be due to it
favorably positioning the guide strand in the Ago2-middle (MID)
domain. We used PyMOLmodeling to observe structural changes be-
tween siRNAs, with or without 20-OMe, at this position. There is no
crystal structure available for 20-mer siRNA guide strands, so we
superimposed the crystal structure of human Ago2 loaded with a
21-mer modified siRNA onto the crystal structure of Ago2 with a
21-mer unmodified siRNA (Figure 6). The modified siRNA main-
tained the alternating 20-OMe/-F pattern in the seed. In the context
of this chemical pattern, position 5 is 20-OMe. Figure 6B shows a
slight shift in positioning of the modified guide strand, starting at po-
sition 5, relative to the unmodified guide strand within the Ago2-MID
domain. Substitution with 20-F, which is more similar in structure to
the unmodified 2’-hydroxyl (20-OH),21 may better maintain the struc-
ture of native RISC complexed with naturally occurring, unmodified
siRNA guide strands that are optimally configured within the seed re-
gion to recognize their mRNA target.
The negative impact of 20-OMe at 30 termini of 20-mer guide strands
may be explained by its disruption to interactions between 30 guide
strand termini and the PAZ domain of Ago2. The 20-OMe 30 terminal
modification is naturally occurring and likely enhances the stability of
Piwi-interacting RNAs in Drosophila melanogaster.22,23 We sought to
visualize the structural impact of this modification in the context of
human Ago2 and compare it to Drosophila Ago. With the use of Py-
MOL modeling, we superimposed the crystal structure of the
Drosophila Ago-PAZ domain complexed with a 30 end 20-OMe
9-mer RNA onto the crystal structure of human Ago2 complexed
Figure 5. Introduction of an Additional 20-Fluoro in the Guide Strand Seed Does Not Impact the Thermal Melting Temperatures of siRNA Guide Strands and
Their RNA Targets within the Seed Region
(A) Schematic representations of guide strand chemical modification patterns used; symbols next to each schematic are used in graphs shown in (B). Legend shows
corresponding chemical structures for 20-ribose chemistries. (B) Thermal melt curves for siRNA guide strands (positions 1–8) and their targets within the seed region (i.e.,
guide strand positions 2–8). Target name and start site of target sequence are indicated in graphs; Tm values are displayed in graph legends.
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with a 21-mer unmodified siRNA. Figure 7B shows Drosophila Ago
with the 30 end 20-OMe 9-mer RNA and the unmodified siRNA guide
strand. The closest contact to the 20-OMe is 4.1 Å away. In human
Ago2 (Figure 7C), the unmodified 20-OH is also 4.1 Å apart from
its closest contact. However, the 30 end 20-OMe 9-mer RNA more
closely occupies the space of its closest contact, tyrosine 338, which
is only 3.6 Å apart. This model suggests that the 30 end 20-OMemodi-
fied siRNA guide strand may not be properly accommodated by the
Ago2-PAZ domain due to steric hindrance. Although this is only a
model, it provides a potential explanation for the observed negative
impact of the 30 terminal 20-OMe modification on human guide
strand-loaded RISC function.
Naturally occurring siRNAs are 19–23 nt long,24,25 but because there
is no crystal structure available for siRNAs with 20-mer guide strands,
we cannot visualize how the 30-terminal nucleotide of a 20-mer guide
strand interacts with Ago2-PAZ. Instead, Figure 7D displays Ago2
loaded with a 21-mer unmodified guide strand. The last two nucleo-
tides, guide strand positions 20 and 21, are securely anchored into the
PAZ domain-binding pocket. However, our 20-mer guide strand may
be too short to similarly anchor itself in the PAZ domain once its 50
end is anchored into the MID domain. The introduction of 20-OMe at
its terminal position (in place of 20-F or 20-OH) may exacerbate any
already-existing issues it has anchoring into Ago2-PAZ. Since 20-F
is more structurally similar to 20-OH, 20-mer guide strands with 30-
terminal 20-F may be able to better contact residues important for
anchoring within Ago2-PAZ.
The inclusion of 20-OMe at the 30 guide strand terminus may disrupt
the proper positioning of the siRNA guide strand within human
Ago2-PAZ, and in turn, this may suboptimally position the guide
strand for finding its target and/or positioning its target for cleavage,
which could explain our observation that including 20-F at guide
strand position 5 partially recovers activity for these guide strands.
This hypothesis is consistent with the model proposed by Tomari
and Zamore26 and is supported by recent kinetics studies,27 which
show that an siRNA guide strand must first anchor within Ago2-
PAZ to allow for initial target binding in the seed region but then
must also detach from the PAZ domain to pair with its target past
the seed region to position the target for cleavage. Consistent with
this model, a 20-mer siRNA guide strand maintaining 20-F at its 30
end, may conform enough to the structure of native RNA to allow
for its initial anchoring in the PAZ domain, and its shorter length
may later facilitate its detachment from the PAZ domain. A 20-mer
guide strand with 20-OMe at its 30 end may never successfully anchor
into the PAZ domain, which may result in suboptimal positioning for
interactions with its target.
The negative impact of the 30 terminal 20-OMe modification on RISC
function may be specific to siRNAs with 20-mer guide strands. The
pronounced negative effect on target silencing that we observed
with this modification change was only demonstrated for siRNAs
with 20-mer guide strands. The inclusion of 20-OMe at the end of
19-mer guide strands did not negatively impact activity as much as
it did for 20-mer guide strands. It is possible that 19-mer guide
strands do not anchor into Ago2-PAZ as well as 20- or 21-mer guide
strands, which may be why all but one sequence demonstrated overall
reductions in efficacy when 19- instead of 20-mer guide strands were
used (Figure S6; Table S7). If this is the case, then the contribution of
the 30 terminal modification on efficacy would be reduced for 19-mer
guide strands, as was observed. In addition, siRNAs with 21-nt long
guide strands were not negatively affected by 30 terminal 20-OMe;
for two sequences, this modification statistically improved efficacy
(p < 0.0001).
Since lead clinical candidates possess 20-OMe modifications at the 30
guide strand termini, the observation that 20-OMe modification at 30
guide strand termini negatively affects RISC function may be some-
what surprising. However, most clinical compounds possess longer
(i.e., 21- to 23-mer) guide strands. Indeed, Alnylam’s “standard,”
“enhanced,” and “advanced enhanced stabilization” chemistries uti-
lize 23-mer guide strands, which likely anchor in the PAZ domain
more efficiently than 20-mer guide strands. If this is the case, then
it may be beneficial for clinical candidates with longer guide strands
to contain 20-OMe at the 30 end to facilitate detachment.
Taken together, our results indicate a cooperative impact of siRNA
structure, chemical modification pattern, and sequence on RISC in-
teractions and highlight the importance of considering all 3 parame-
ters when designing siRNAs for screening purposes. They also offer
improved design rules for 20-/15-mer siRNAs maintaining the alter-
nating 20-OMe/-F guide strand pattern described by Allerson et al.7
This chemical pattern is widely used in research, because it affords ac-
tivity to many siRNA sequences, the asymmetric structure evaluated
in these studies has been previously demonstrated to be efficiently
internalized into cells,2 and we show that a 20-mer guide strand
Figure 6. Replacing 20-O-Methyl with 20-Fluoro at
Guide Strand Position 5 May Enhance siRNA-Target
Interactions in the Seed
(A) Crystal structure of Ago2 loaded with a 21-mer un-
modified siRNA guide strand (light magenta), optimally
positioned to pair with its mRNA target (gray) in the seed
(positions 2–8). (B) Image, as shown in (A), but also
including a fully chemically modified 21-mer siRNA guide
strand (black) with an alternating 20-OMe/-F chemical
pattern within its seed and 20-OMe modification at position 5. Both siRNA sequences contain cysteine at guide strand position 5 (circled in red), but the chemically modified
siRNA is positioned differently than the unmodified siRNA at this site, which may disrupt target binding.
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provides similar or better efficacy than its comparable 21-mer guide
strand for multiple siRNA sequences (Figure S7; Table S8). In the
contexts of this chemical-modification pattern, siRNA structure,
and guide strand length, the incorporation of 20-F at guide strand po-
sitions 5 and 20 may be a better design rule than the standard 20-
OMe/-F alternating pattern for fully modified siRNAs used for
research applications.
The application of chemical modifications to siRNAs impacts their in-
teractions with other proteins, besides Ago2, that were not evaluated
here. For example, chemical modifications inhibit siRNA recognition
by the innate immune system and degradation by nucleases. Both 20-F
and 20-OMemodifications have been previously demonstrated to abro-
gate activation of Toll-like receptors;28 therefore, we do not expect these
types of interactions to contribute to our observed effects. However,
these modifications may differentially impact nuclease stability. Thus,
in the future, it will be important to elucidate the impacts of 20-OMe,
20-F, and 20-OH at 30 guide strand termini on 30 stabilization in vivo.
It will also be interesting to look at the impacts of other chemical mod-
ificationswidely used in research for 30 stabilization, like inverted deoxy-
thymidine, in the context of our 20-mer guide strands, on both siRNA
efficacy and guide strand 30 stabilization. The primary nuclease activity
against single-stranded 30 siRNA guide strand overhangs in serum is
processive 30-exonuclease digestion,29,30 but the primary RNAdegrada-
tionmechanism bymost RNases occurs through the attack of ribose 20-
OH on its 30 phosphate backbone, and the 30 phosphate is not naturally
present at the 30 terminus. Therefore, the stabilizing effects of 20-F versus
20-OMe at this position may be relatively similar.
MATERIALS AND METHODS
Oligonucleotide Synthesis, Deprotection, and Purification
Oligonucleotides were synthesized using standard andmodified (2ʹ-F,
2ʹ-OMe) phosphoramidite, solid-phase synthesis conditions using a
MerMade 12 (BioAutomation, Irving, TX, USA) and Dr. Oligo 48
Medium Throughput Oligo Synthesizer (Biolytic; #403-104814).
Cholesterol-conjugated oligonucleotides were synthesized on modi-
fied solid support (Chemgenes; #N-9166-05). Oligonucleotides were
removed from controlled pore glass (CPG), deprotected, and purified
by high-performance liquid chromatography (HPLC), as described
previously,31 or ethanol precipitated (for sequences, chemical modifi-
cation patterns, and purification methods, see Table S10). Purified ol-
igonucleotides were passed over a Hi-Trap cation exchange column to
exchange the counter-ion with sodium. All oligonucleotide identites
were confirmed by HPLC-mass spectrometry.
Cell Culture (HeLa and WM-115 cells)
HeLa cells (ATCC; #CCL-2) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Cellgro; #10-013CV), and WM-115 cells
(ATCC; CRL-1676) were maintained in Eagle’s minimum essential
medium (EMEM) (Sigma-Aldrich; M0643). The media were supple-
mented with 9% fetal bovine serum (FBS) (Gibco; #26140), and all
cells were grown at 37C and 5% CO2. Cells were split every 2 to
7 days and discarded after fifteen passages.
Direct Delivery (i.e., Passive Uptake) of Oligonucleotides
sFLT1-i13_2283 and sFLT1-e15a_2519, HeLa Cells
cDNA sequences, corresponding to 20-nt-long, unique regions of
sFLT1-i13 and sFLT1-e15a target mRNAs, were cloned into a psi-
Check-2 vector (Promega, Madison, WI, USA; C8021), according
to the manufacturer’s protocol. HeLa cells were plated on a 10-cm
dish and transfected with 24 mg of the psiCheck-2 plasmid using Lip-
ofectamine 2000 (Invitrogen, Carlsbad, CA, USA; 11668019), accord-
ing to the manufacturer’s protocol. Cells were transferred to 96-well
cell-culture plates, 24 h later.
All Targets, All Cells
HeLa cells were diluted in DMEM containing 6% FBS, and WM-115
cells were diluted in EMEM containing 4.5% FBS to 8,000–10,000
Figure 7. Including 20-O-Methyl at the 30 End of an siRNA Guide Strand May Disrupt Its Anchoring in Ago2-PAZ
(A) Legend shows corresponding chemical structures for 30 end 20-ribose chemistries. (B) Crystal structure of the Drosophila Ago-PAZ domain (yellow), loaded with a 9-mer
small RNA (black) with 20-OMe at its 30 end. Image also includes a 21-mer unmodified siRNA guide strand (raspberry). The distances between the 30 ends of each small RNA
and the closest residue in Drosophila Ago (LEU707) are shown. (C) Crystal structure of human Ago2-PAZ (deep teal), loaded with a 21-mer unmodified siRNA guide strand
(light pink). Image also includes a 9-mer small RNA (black) with 20-OMe at its 30 end. The distances between the 30 ends of each small RNA and the closest residue in Ago2
(TYR338) are shown. (D) Crystal structure of human Ago2-PAZ (deep teal), loaded with a 21-mer unmodified siRNA guide strand (light pink) showing positions 20 and 21
anchored into the binding pocket of the PAZ domain.
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(HeLa) or 25,000 (WM-115) cells per 50 mL. siRNAs were diluted to
twice the final maximum test concentration in OptiMEM (Carlsbad,
CA, USA; 31985-088) and serially diluted to create 7-point dose re-
sponses. 50 mL of diluted siRNA was added to 50 mL of cells, resulting
in a final concentration of 1.5 mM siRNA for the maximum dose and
3% or 2.25% FBS. Cells were incubated for 72 h at 37C and 5% CO2.
Method for Quantitative Analysis of Target mRNA Expression
sFLT1-i13_2283 and sFLT1-e15a_2519, HeLa Cells
mRNA was quantified using the Dual-Glo Luciferase Assay System,
according to the manufacturer’s protocol (Promega; #E2940). Lumi-
nescence was detected on a Veritas Luminometer (Promega; #998-
9100) or a Tecan M1000 (Tecan, Morrisville, NC, USA). For each
cell-treatment plate, data were normalized to control reporter firefly
luciferase (fLuc) and plotted as a percentage of the mean results
from untreated cells.
sFLT1-i13_2283 and sFLT1-e15a_2519, WM-115 cells; HTT_X,
HeLa cells
mRNA was quantified using the QuantiGene 2.0 assay kit (Affyme-
trix; QS0011). Cells were lysed in 250 mL diluted lysis mixture
composed of 1 part lysis mixture (Affymetrix; 13228), 2 parts H2O,
and 0.167 mg/mL proteinase K (Affymetrix; QS0103) for 30 min at
55C. Probe sets for human sFLT1-i13, sFLT1-e15a, HTT, and
HPRT (Affymetrix; SA-50459, SA-50496, SA-50339, SA-10030)
were diluted and used according to the manufacturer’s recommended
protocol. Cell lysates were mixed thoroughly before 20–60 mL of
lysate and 20 mL of probe set mixture were added to each well of a cap-
ture plate in triplicate. 20–60 mL of lysis mixture, diluted in 2 parts
H2O, was also added, such that each well contained 100 mL total.
For each cell-treatment plate, HPRT was used as a normalization
and/ or visual control, and data were plotted as a percentage of the
mean results from untreated cells.
Statistical Analyses
Dose-response data were analyzed using GraphPad Prism 8.3.0 soft-
ware (GraphPad Software, San Diego, CA, USA). Concentration-
dependent IC50 curves were fitted using the log(inhibitor) versus
response – variable slope (four parameters) method. The lower limit
of the curve was set to >0, and the upper limit of the curve was set to
>95. Statistical outliers were identified using Q = 1% and excluded
from calculation of the fitted curve but shown on the graphs as solid
points. If the R-squared value for the fitted curve was <0.8, then the
IC50 value is marked in its table, and its curve is shown as a dashed
line in its graph. If the Prism calculated IC50 value was >1.5 mM
(i.e., greater than the top treatment dose), then the IC50 value was
not included in its table, and IC50 fold change was not calculated. p
values were calculated using two-way ANOVA (analysis excluded sta-
tistical outliers identified as previously described). AUCs were calcu-
lated using automatic software settings, i.e., baseline: y = 0, minimum
peak height: ignore peaks < 10% of the distance from Ymin to Ymax
(analysis excluded statistical outliers identified, as previously
described).
Tm Experiments and Calculations
Samples were diluted in 1 Dulbecco’s phosphate-buffered saline
(PBS) (Sigma-Aldrich; D8662), and A260 values were collected at
1C/1 min intervals over three ramps: 25C–95C, 95C–25C, and
25C–95Cwith 1 PBS blank correction using Agilent Technologies
(Agilent) Cary 100 Series UV-Vis Spectrophotometer (Agilent;
#G9821A). The readings from the third ramp for data shown in Fig-
ure 4 or the second ramp for data shown in Figure 5 were minimum-
maxiumum (min-max) normalized and plotted. Tm was calculated
using GraphPad Prism 8.3.0 software.
PyMOL Modeling
For all figures, the crystal structures of human Ago2 loaded with a 21-
mer unmodified siRNA guide strand (PDB: 4W5N), human Ago2
loaded with a 21-mer unmodified siRNA guide strand bound to its
target (PDB: 4W5Q), and human Ago2 loaded with a 21-mer modi-
fied siRNA guide strand (PDB: 5JS2) were loaded into PyMOL
(Schrödinger)
Ago2 (chain A) from PDB:4W5Q and PDB: 5JS2 were superimposed
onto Ago2 (chain A) from PDB: 4W5N and then hidden, leaving only
Ago2 from PDB: 4W5N (the most thoroughly resolved Ago2 struc-
ture) and guide strands from PDB: 4W5N, PDB: 4W5Q, and PDB:
5JS2 and the target from PDB: 4W5Q. The MID (Gly445-Ile577),
PIWI (Leu579-Ala859), and PAZ (Pro229-Val347) domains of hu-
man Ago2 from PDB: 4W5N were selected and colored pale cyan,
cyan, and deep teal, respectively, and all but these three domains in
Ago2 from PDB: 4W5N (chain A) were hidden.
The 21-mer unmodified guide strand from PDB: 4W5N (nucleotides
1–7 and 12–21 resolved) was light pink. The 21-mer unmodified
guide strand from PDB: 4W5Q (nucleotides 1–18 resolved) was light
magenta. The guide strand-bound target from PDB: 4W5Q (nucleo-
tides 1–9 resolved) was gray 50. The 21-mer modified guide strand
from PDB: 5JS2 (residues 1–6 resolved) was black.
The crystal structure of Drosophila Ago-PAZ loaded with a 9-mer 30
end 20-O-methylated small RNA (PDB: 3MJ0) was loaded into Py-
MOL. Drosophila Ago-PAZ (chain A) from PDB: 3MJ0 was superim-
posed onto the Ago2-PAZ domain in 4W5N and colored yellow. The
9-mer 30 end 20-O-methylated small RNA (nucleotides 1–9 resolved)
was black.
For the Graphical Abstract, the MID, PIWI, and PAZ domains of
Ago2, nucleotides 19–20 in the 21-mer unmodified guide strand
from PDB: 4W5N, and all resolved nucleotides in the 21-mer unmod-
ified guide strand and bound target from PDB: 4W5Q are shown.
For Figure 6A, the MID, PIWI, and PAZ domains of Ago2 from PDB:
4W5N and all resolved nucleotides in the 21-mer unmodified guide
strand and bound target from PDB: 4W5Q are shown. For Figure 6B,
the MID, PIWI, and PAZ domains of Ago2 from PDB: 4W5N, all
resolved nucleotides in the 21-mer unmodified guide strand and
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bound target from PDB: 4W5Q and all resolved nucleotides in the 21-
mer modified guide strand from PDB: 5JS2 are shown.
For Figure 7B, Ago-PAZ and all resolved nucleotides in the 9-mer 30
end 20-O-methylated small RNA from PDB: 3MJ0 and all resolved
nucleotides in the 21-mer unmodified guide strand from PDB:
4W5N are shown. For Figure 7C, the PAZ domain of Ago2, all
resolved nucleotides in the 21-mer unmodified guide strand from
PDB: 4W5N, and all resolved nucleotides in the 9-mer 30 end 20-O-
methylated small RNA from PDB: 3MJ0 are shown. For Figure 7D,
the PAZ domain of Ago2 and all resolved nucleotides in the 21-
mer unmodified guide strand from PDB: 4W5N are shown.
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